Tigis

Ročníky Psychiatrie

OBSAH

EDITORIAL
Tomáš Kašpárek...................................................................................................................... 46

VZPOMÍNÁNÍ NA PROF. CYRILA HÖSCHLA....................................................................... 47

OBSAH................................................................................................................................... 59

PŮVODNÍ PRÁCE

Ivana Tašková, Nicole Šafářová
CYPRI: skórovací systém pro výběr psychiatrických pacientů
jako vhodných kandidátů 
pro farmakogenetické vyšetření..................................................... 61

PŘEHLEDNÉ ČLÁNKY

Jiří Koutek, Jana Kocourková, Jakub Kerner, David Kolouch
Deprese, sebepoškozování a suicidalita v dětství a adolescenci............................................ 68

Martin Hýža
Farmakoterapie schizofrenie při komorbidním abúzu
se zaměřením na D3 receptor.................................................................................................. 75

Jonáš Boček, Dana Končelíková, Jan Pelíšek
Postcovid syndrom se zaměřením na úzkostné projevy.......................................................... 79

Jiří Patočka, Zdeňka Navrátilová, Sandra Maria Barbalho, Kamil Kuča
Rohatec růžkatý (Glaucium corniculatum (L.) Rudolph)
a jeho neuroprotektivní účinky................................................................................................. 84

ZPRÁVY

Luboš Brabenec
Transkraniální magnetická stimulace: Technologie budoucnosti slaví 40 let........................... 90

Sdělení šéfredaktora................................................................................................................ 90

Pozvánka na přednášku (NEJEN) VLNY.................................................................................. 91

M. Kopeček
Tip na četbu.............................................................................................................................. 91

POKYNY AUTORŮM................................................................................................................92

CONTENTS

EDITORIAL
Tomáš Kašpárek....................................................................................................................... 46.

REMINISCENCES OF PROFESSOR CYRIL HÖSCHL........................................................... 47

CONTENTS.............................................................................................................................. 59

ORIGINAL PAPERS

Ivana Tašková, Nicole Šafářová
CYPRI: A scoring system for selecting psychiatric patients
as suitable candidates 
for pharmacogenetic testing................................................................... 61

REVIEWS

Jiří Koutek, Jana Kocourková, Jakub Kerner, David Kolouch
Depression, self-harm and suicidality in childhood and adolescence......................................... 68

Martin Hýža

Pharmacotherapy of schizophrenia in comorbid substance
use disorder focused 
on D3 receptor............................................................................................ 75

Jonáš Boček, Dana Končelíková, Jan Pelíšek`
Post-covid syndrome with a focus on anxiety symptoms............................................................. 79

Jiří Patočka, Zdeňka Navrátilová, Sandra Maria Barbalho, Kamil Kuča`
Glaucium corniculatum (L.) Rudolph and its neuroprotective effects........................................... 84

NEWS

Luboš Brabenec
Transcranial Magnetic Stimulation: A Future Technology
Celebrates 40 Years..................................................................................................................... 90

Editor's Note................................................................................................................................. 90

Invitation to the Lecture on (NOT ONLY) Waves ......................................................................... 91

M. Kopeček
A reading recommendation........................................................................................................... 91

INSTRUCTIONS FOR AUTHORS................................................................................................ 92

OBSAH

EDITORIAL ..................................................................................................................................... 1

OBSAH ........................................................................................................................................... 2

PROGRAM ...................................................................................................................................... 4

ODBORNÁ SYMPOZIA ................................................................................................................... 7

PLENÁRNÍ PŘEDNÁŠKY .............................................................................................................. 40

ÚVOD K VÝVĚSKOVÝM SDĚLENÍM ............................................................................................ 41

VÝVĚSKOVÁ SDĚLENÍ ................................................................................................................ 42

REJSTŘÍK ...................................................................................................................................... 51

CONTENTS

 
EDITORIAL ...................................................................................................................................... 1

CONTENTS ..................................................................................................................................... 2

PROGRAM ....................................................................................................................................... 4

SCIENTIFIC SYMPOSIA .................................................................................................................. 7

PLENARY TALKS ........................................................................................................................... 40

INTRODUCTION TO POSTERS .................................................................................................... 41

POSTERS ....................................................................................................................................... 42

INDEX .............................................................................................................................................. 51

OBSAH

EDITORIAL

Miloslav Kopeček.............................................................................................................................1

OBSAH .......................................................................................................................................... 3

PŮVODNÍ PRÁCE

Martina Janíková, Karolína Zuzánková, Dagmar Schwambergerová, Lenka Martinec
Nováková, Anna Francová, Barbora Darmová, Pavla Stopková, Iveta Fajnerová
Expozice ve virtuální realitě obohacená o čichové podněty
u obsedantně-kompulzivní poruchy: studie proveditelnosti ...............................................................5

PŘEHLEDNÉ ČLÁNKY

Kamila Růžková, David Bayer, Martin Mžik
Gama-hydroxybutyrát a 1,4-butanediol
Potenciálně nebezpečné návykové látky – přehled a kazuistika ........................................................9

Filip Tylš
Ketaminem asistovaná psychoterapie v klinické praxi....................................................................... 15

Martina Váhalová, Iva Holmerová
Závislosti na nelegálních návykových látkách v seniorském věku ..................................................... 23

Karolína Vlčková
Role psychologa v paliativním týmu ................................................................................................... 28

Zdeňka Navrátilová, Jiří Patočka
Klitorie ternatská (Clitoria ternatea L.) – motýlí hrách a jeho účinky
na nervový systém............................................................................................................................... 32

ZPRÁVY

Profesoru Pavlu Mohrovi je 60 let......................................................................................................... 36

Ohlédnutí za 67. česko-slovenskou psychofarmakologickou konferencí ............................................. 38

Sdělení šéfredaktora ............................................................................................................................. 40

Karel Nešpor, Jaroslav Veselý
Návykové nemoci a trestná činnost ....................................................................................................... 40

DOPISY, OHLASY, DISKUSE

Diskusní příspěvek ke článku Psychiatrizace: možná příčina i následek alarmujícího
stavu duševního zdraví adolescentů, Psychiatrie č. 4/2024 ....................................................................41

Ještě jednou k přínosu psychiatrického výzkumu ....................................................................................44

PŘEDPLATNÉ..........................................................................................................................................45

CONTENTS

EDITORIAL

Miloslav Kopeček.........................................................................................................................................1

CONTENTS................................................................................................................................................. 3

ORIGINAL PAPERS

Martina Janíková, Karolína Zuzánková, Dagmar Schwambergerová,
Lenka Martinec Nováková, Anna Francová, Barbora Darmová, Pavla Stopková,
Iveta Fajnerová
Olfactory-Enriched Virtual Reality Exposure
in Obsessive-Compulsive Disorder: A Feasibility Study................................................................................5

REVIEWS

Kamila Růžková, David Bayer, Martin Mžik
Gama-hydroxybutyrate and 1,4-butenediol
potentially dangerous addictive substances – an overview and case report ...............................................9

Filip Tylš
Ketamine-Assisted Psychotherapy in clinical practice .............................................................................. 15

Martina Váhalová, Iva Holmerová
Addictions in the older age ....................................................................................................................... 23

Karolína Vlčková
The role of the psychologist in the palliative care team ........................................................................... 28

Zdeňka Navrátilová, Jiří Patočka
Blue ternate (Clitoria ternatea L.) – Butterfly pea and its effects
on the nervous system.............................................................................................................................. 32

NEWS

Professor Pavel Mohr is celebrating his 60th birthday .............................................................................. 36

A Retrospective on the 67th Czech-Slovak Psychopharmacological Conference......................................38

Message from the Editor-in-Chief.............................................................................................................. 40

Karel Nešpor, Jaroslav Veselý
Addictive Disorders and Criminal Activity................................................................................................... 40

CORRESPONDENCE

Discussion to the Article "Psychiatrization: A Possible Cause and Effect
of the Alarming State of Adolescent Mental Health", Psychiatry No. 4/2024.............................................41

Once Again on the Contribution of Psychiatric Research .........................................................................44

SUBSCRIPTION ........................................................................................................................................45

OBSAH

EDITORIAL ............................................................................................................................................. 1

OBSAH ................................................................................................................................................... 2

PROGRAM ............................................................................................................................................. 4

ODBORNÁ SYMPOZIA ........................................................................................................................ 10

Sympozium společnosti pro biologickou psychiatrii – emoční dysregulace napříč
psychickými poruchami ......................................................................................................................... 10

Limity a možnosti léčby antipsychotiky a neurostimulačními metodami ................................................12

Neprávem opomíjený a obávaný klozapin .............................................................................................12

Neinvazivní mozková stimulace (NIBS) napříč neuropsychiatrií – od výzkumu
ke klinické praxi ......................................................................................................................................13

Sympózium Psychofarmakologickej sekcie SPsS ..................................................................................14

Mikrobiom a možnosti jeho interakce s psychofarmaky .........................................................................16

Novinky v léčbě poruch příjmu potravy ...................................................................................................17

Ketaminem asistované psychoterapie (KAP) v léčbě celého neurotického spektra ..............................18

Nová vodítka psychiatrické společnosti ČLS JEP pro léčbu deprese ....................................................20

Intenzivní péče v psychiatrii ....................................................................................................................21

Psychedelika, problémové děti psychofarmakologie V: Stále problémové,
`nebo budoucnost? ................................................................................................................................22

Gerontopsychiatrie .................................................................................................................................23

Znepokojivé trendy v psychofarmakologii u dětí a adolescentů: Od nešťastné
psychopatologie k medicinalizaci ...........................................................................................................24

Děti, jejichž matky užívaly v těhotenství psychofarmaka: Medikovat, či nemedikovat
těhotné? ................................................................................................................................................ 25

Nové pokroky v oblasti VR terapie (terapie virtuální realitou): Ohlédnutí
za konferencí ICDVRAT 2024 ............................................................................................................... 26

Farmakodetektivky 2 ............................................................................................................................28

Neuropsychiatrické aspekty digitálních závislostí ................................................................................29

Psychedelika, problémové děti psychofarmakologie – neurobiologické okénko ..................................30

Inovace a výzvy v léčbě sexuálních dysfunkcí: od robotů po farmakologické přístupy ........................32

NOVÝ VÝZKUM ................................................................................................................................... 33

Zvýšenie endokanabinoidnej signalizácie ako cieľ pre farmakoterapiu
úzkostných
a kognitívnych porúch ....................................................................................................... 33

Nárůst sérových hladin olanzapinu vlivem akutního zánětu ................................................................33

Vliv CB1 antagonisty / inverzního agonisty AM251 na metabolickou aktivitu P450:
`In vitro studie ..................................................................................................................................... 34

Vybrané génové varianty a odpoveď na liečbu escitalopramom u pacientov s diagnózou
depresívnej poruchy ........................................................................................................................... 34

Vztah mezi sérovou koncentrací 25(OH) vitaminu D, verbální pamětí a objemem
hipokampální šedé hmoty u pacientů s první epizodou schizofrenie ................................................. 34

Pravděpodobnostní kvantifikace trendu vlasového kortisolu pro dlouhodobé
monitorování terapie .......................................................................................................................... 35

Dynamika frontálního EEG jako indikátor odpovědi na antidepresivní léčbu:
Retrospektivní analýza pomocí Hurstova exponentu u pacientů s depresivní poruchou .................. 35

Medikační trajektorie antipsychotik a váhový přírůstek u prvotně hospitalizovaných
pacientů s první epizodou psychotického onemocnění ..................................................................... 36

VÝVĚSKOVÁ SDĚLENÍ .....................................................................................................................37

Preklinická P1–P11.................................................................................................................................37

Klinická K1–K16 .....................................................................................................................................41

WORKSHOPY ....................................................................................................................................... 49

Pohádky 1000+1 noci: interaktivně pojaté kazuistické střípky psychedelických ponorů
do nevědomého materiálu z více než tisíce ketaminových procesů na Klinice Psyon ...........................49

Algoritmus podávání off-label ketaminu v psychiatrii ................................................................................ 49

Práce s přepisem v imaginaci u transgeneračního traumatu .................................................................... 49

Deeskalace agitovaného pacienta ............................................................................................................ 50

Léčba závažných příznaků vybraných duševních poruch – EBM, umění, nebo magie?........................... 50

Farmakologická léčba ADHD u dospělých ................................................................................................ 50

REJSTŘÍK ................................................................................................................................................ 51

CONTENTS

EDITORIAL ................................................................................................................................................. 1

CONTENTS ................................................................................................................................................ 2

PROGRAM ................................................................................................................................................. 4

SCIENTIFIC SYMPOSIA ...........................................................................................................................10

Society for Biological Psychiatry Symposium– emotional dysregulation
across
psychiatric disorders ........................................................................................................................10

Limits and possibilities of treatment with antipsychotics and neurostimulation methods ......................... 12

Unjustly neglected and feared clozapine .................................................................................................. 12

Non-invasive brain stimulation (NIBS) across neuropsychiatry – from research
to clinical practice ......................................................................................................................................13

Symposium of the Psychopharmacological Section of the Slovak Psychiatric Society ............................ 14

The microbiome and its potential interactions with psychopharmacs ....................................................... 16

News in the treatment of eating disorders ................................................................................................. 17

Ketamine-assisted psychotherapy (KAP) in the treatment of the entire neurotic spectrum ...................... 18

New guidelines of Czech Psychiatric Society for treatment of depression ............................................... 20

Psychiatric intensive care ......................................................................................................................... 21

Psychedelics problem children of psychopharmacology V: Still problematic, or the future?..................... 22

Gerontopsychiatry .................................................................................................................................... 23

Disturbing Trends in Psychopharmacology in Children and Adolescents: From
unfortunate psychopathology to medicalization ....................................................................................... 24

Children whose mothers took psychopharmaceuticals during pregnancy: To medicate,
or not to medicate pregnant women? ....................................................................................................... 25

New advances in VR (virtual reality) therapy: A look back at the ICDVRAT 2024 conference ................. 26

Psychopharmacs detective stories 2nd .................................................................................................... 28

Neuropsychiatric aspects of digital addictions ......................................................................................... 29

Psychedelics, problem children of the psychopharmacology – neurobiological window ......................... 30

Innovations and challenges in the treatment of sexual dysfunctions: From robots
to pharmacological approaches ............................................................................................................... 32

NEW RESEARCH ................................................................................................................................... 33

Enhancement of endocannabinoid signaling as a target for pharmacotherapy
of anxiety and cognitive disorders ............................................................................................................ 33

Increase in serum olanzapine levels in acute inflammation ..................................................................... 33

Effect of the CB1 antagonist / inverse agonist AM251 on P450 metabolic activity:
An in vitro study ........................................................................................................................................ 34

Selected gene variants and escitalopram treatment response in patients
with depressive disorder ........................................................................................................................... 34

A relationship between 25(OH) vitamin D serum level, verbal memory and hippocampal
gray matter volume in first episode schizophrenia patients ...................................................................... 34

Probabilistic quantification of hair cortisol trend for long-term therapy monitoring ................................... 35

Frontal eeg dynamics as indicators of antidepressant response:
A Hurst exponent-based retrospective analysis in major depression disorder ......................................... 35

Trajectories of daily antipsychotic use and weight gain in people hospitalized
for first episode of psychosis .................................................................................................................... 36

POSTERS ................................................................................................................................................ 37

Preclinical P1–P11 ...................................................................................................................................37

Clinical K1–K16 .................................................................................................................. .................... 41

WORKSHOPS ......................................................................................................................................... 49

Tales of 1000+1 nights: interactively conceived casuistic shards of psychedelic dives
into unconscious material from over a thousand of ketamine processes at the Psyon Clinic .................. 49

Algoritm for off-label use of ketamine in psychiatry................................................................................... 49

Working with imagery rescripting in transgenerational trauma ................................................................ 49

Deescalation of agitated patient .............................................................................................................. 50

Treatment of severe symptoms of selected mental disorders – EBM, art, or magic? ............................. 50

Pharmacological treatment of ADHD in adults ........................................................................................ 50

INDEX ..................................................................................................................................................... 51

středa, 08 leden 2025 13:00

Psychiatrie suppl. 1/2024

Napsal(a)

Ve výstavbě

OBSAH

EDITORIAL
Jan Vevera...................................................................................................................................129

OBSAH........................................................................................................................................132

PŘEHLEDNÉ ČLÁNKY

Vojtěch Pišl, Tereza Kohutová, Jan Vevera
Psychiatrizace: možná příčina i následek alarmujícího stavu duševního zdraví
adolescentů...................................................................................................................................134

Linda Soukupová, Daniela Dudysová, Jana Kopřivová
Akustická stimulace pomalých oscilací během spánku ............................................................... 141

Petr Dungl
Laboratorní nálezy u osob s alkoholovou epilepsií....................................................................... 148

Petra Řehořková, Lucie Švandová, Martina Sebalo Vňuková, Michaela Poslt Königová,
Radek Ptáček
Zákroky estetické medicíny a jejich psychopatologické souvislosti ...............................................152

PŘEHLEDNÉ ČLÁNKY

Zdeňka Navrátilová, Jiří Patočka
Mangostan: lahodné ovoce se slibnými účinky...............................................................................159

FÓRUM ČESKÉ NEUROPSYCHOFARMAKOLOGICKÉ SPOLEČNOSTI

Libor Ustohal, Jana Hořínková
Léčba psychózy u Parkinsonovy nemoci.........................................................................................164

ZPRÁVY

Profesoru Cyrilu Höschlovi je 75 let................................................................................................ 168

Vzpomínka na pana profesora Ptáčka............................................................................................. 169

DOPISY, OHLASY, DISKUSE

Václav Filip`
Diskusní příspěvek k editorialu Richarda Balona, Psychiatrie č. 3/2024...........................................169

REJSTŘÍKY 2024..............................................................................................................................170

POKYNY AUTORŮM..........................................................................................................................173

 

CONTENTS

EDITORIAL
Jan Vevera...........................................................................................................................................129

CONTENTS..........................................................................................................................................132

ORIGINAL PAPERS

Vojtěch Pišl, Tereza Kohutová, Jan Vevera
Psychiatrization: possible cause and effect of the alarming state of adolescent
mental health........................................................................................................................................134

Linda Soukupová, Daniela Dudysová, Jana Kopřivová
Acoustic stimulation of slow oscillations during sleep.......................................................................... 141

Petr Dungl
Laboratory findings of patients with alcohol-induced seizures............................................................. 148

Petra Řehořková, Lucie Švandová, Martina Sebalo Vňuková, Michaela Poslt Königová,
Radek Ptáček
Aesthetic medicine interventions and their psychopathological implications ........................................152

ORIGINAL PAPERS

Zdeňka Navrátilová, Jiří Patočka
Mangosteen: a delicious fruit with promising effects..............................................................................159

FORUM OF THE CZECH NEUROPSYCHOPHARMACOLOGICAL SOCIETY

Libor Ustohal, Jana Hořínková
Treatment of psychosis in Parkinson’s disease.......................................................................................164

NEWS

Professor Cyril Höschl 75 years old......................................................................................................... 168

Remembrance of Professor Ptáček......................................................................................................... 169

CORRESPONDENCE

Václav Filip
Discussion contribution to Richard Balon's editorial, Psychiatry No.3/2024.............................................169

INDEX 2024 ............................................................................................................................................ 170

INSTRUCTIONS FOR AUTHORS............................................................................................................173

OBSAH

EDITORIAL

Richard Balon.......................................................................................................................... 85

OBSAH..................................................................................................................................87

PŘEHLEDNÉ ČLÁNKY

Veronika Juríčková, Ladislav Kesner, Dominika Grygarová, Jiří Horáček
Současné možnosti remediace negativních dopadů mediálních zpráv
na duševní zdraví................................................................................................................... 89

Kamila Zvolská, Eva Králíková
Přehlížená diskrepance: zdravý životní styl a kouření............................................................ 95

Jiří Patočka, Zdeňka Navrátilová, Kamil Kuča, Bohumír Plucar
Biologicky účinné metabolity kotrče kadeřavého.................................................................... 99

KAZUISTIKY

Jonáš Boček
Psychotické stavy u pacientů po prodělání covidu-19: série kazuistik.................................. 103

FÓRUM ČESKÉ NEUROPSYCHOFARMAKOLOGICKÉ SPOLEČNOSTI

Miloslav Kopeček, Jiří Masopust
Dlouhodobě působící injekční intramuskulární aripiprazol
aplikovaný jednou za 2 měsíce je připraven k použití............................................................ 108

ZPRÁVY

Pavel Doubek
Druhé Podzimní sympozium České neuropsychofarmakologické společnosti....................... 113

Vanda Franková
Inhibitory acetylcholinesterázy – nová pravidla
úhrady ze zdravotního pojištění............................................................................................... 114

DOPISY, OHLASY, DISKUSE

Cyril Höschl, Filip Španiel
Umění a (neuro)věda.............................................................................................................. 116

Miloslav Kopeček
Orální aplikace ketaminu v tabletách s prodlouženým uvolněním (R-107) byla
efektivní v multicentrické, dvojitě zaslepené, placebem kontrolované studii typu
2 u pacientů s rezistentní depresivní poruchou. Studie BEDROC..........................................124

Pavla Doležalová, Anna Lorenzová
Standardy péče o zdraví transgender a genderově rozmanitých osob,
verze č. 8 
(SOC-8)...................................................................................................................126

POKYNY AUTORŮM....................................................................................................... 128

CONTENTS

EDITORIAL

Richard Balon........................................................................................................................... 85

CONTENTS...........................................................................................................................87

ORIGINAL PAPERS

Veronika Juríčková, Ladislav Kesner, Dominika Grygarová, Jiří Horáček
Current possibilieties for remediation of the negative effects of media news on
mental health............................................................................................................................ 89

Kamila Zvolská, Eva Králíková
An overlooked discrepancy: healthy lifestyle and smoking....................................................... 95

Jiří Patočka, Zdeňka Navrátilová, Kamil Kuča, Bohumír Plucar
Biologically active metabolites of the cauliflower mushroom..................................................... 99

CASE STUDIES

Jonáš Boček
Psychotic conditions among patients in the aftermath of COVID-19:
case histories .......................................................................................................................... 103

FORUM OF THE CZECH NEUROPSYCHOPHARMACOLOGICAL SOCIETY

Miloslav Kopeček, Jiří Masopust
Long-acting injectable intramuscular aripiprazol ready-to-use
every 2 months........................................................................................................................ 108

NEWS

Pavel Doubek
Second Autumn Symposium of the Czech Neuropsychopharmacological Society...................113

Vanda Franková
Acetylcholinesterase inhibitors – new health insurance reimbursement rules.......................... 114

CORRESPONDENCE

Cyril Höschl, Filip Španiel
Arts and Neuroscience – Encounters........................................................................................ 116

Miloslav Kopeček
BEDROC study: Extended-release, oral ketamine (R-107) was effective
in multicenter, randomized, placebo-controlled, phase 2 study in patients
with treatment-resistant major depression..................................................................................124

Pavla Doležalová, Anna Lorenzová
Standards of Care for the Health of Transgender and Gender Diverse People,
Version 8......................................................................................................................................126

INSTRUCTIONS FOR AUTHORS................................................................................... 128

OBSAH

EDITORIAL

Jiří Horáček ............................................................................................................................... 45

OBSAH ...................................................................................................................................47

PŮVODNÍ PRÁCE

Kristína Široká, Annamária Antalová, Daniela Čechová
Copingové stratégie v kontexte psychopatologickej záťaže ..................................................... 49


PŘEHLEDNÉ ČLÁNKY

Pavel Řehulka
Migréna – aktualizace 2024 ..................................................................................................... 55

Zdeňka Navrátilová, Jiří Patočka
Zázvor lékařský (Zingiber officinale Roscoe) a jeho účinky na nervový systém ........................61

VZDĚLÁVÁNÍ

Klára Látalová
Léčba generalizované úzkostné poruchy u specifických populací a možnosti
nových léčebných strategií ........................................................................................................ 68

 TEST ............................................................................................................................................ 76

FÓRUM ČESKÉ NEUROPSYCHOFARMAKOLOGICKÉ SPOLEČNOSTI

Miloslav Kopeček
Bude evenamid budoucím klozapinem v léčbě rezistentní schizofrenie?
Pozitivní 
výsledky nového glutamátového inhibitoru
evenamidu ve studii 008A............................................................................................................77

ZPRÁVY

Přepis proslovu prof. Jana Vevery na pohřbu MUDr. Jana Sikory ............................................. 79

Ladislav Csémy a MUDr. Karel Nešpor
Sociální média a návykové chování............................................................................................. 81

DOPISY, OHLASY, DISKUSE

Radkin Honzák
Spiritualita a medicína.................................................................................................................. 83

PŘEDPLATNÉ

 

 

CONTENTS

EDITORIAL

Jiří Horáček ............................................................................................................................... 45

CONTENTS.............................................................................................................................47

ORIGINAL PAPERS

Kristína Široká, Annamária Antalová, Daniela Čechová
Coping Strategies in the Setting of Psychopatological Burden ................................................. 49

REVIEWS

Pavel Řehulka
Migraine – an update for 2024.................................................................................................. 55

Zdeňka Navrátilová, Jiří Patočka
Ginger (Zingiber officinale Roscoe) and its effects on the nervous system ..............................61

CME

Klára Látalová
Treatment of generalized anxiety disorder in specific populations and the possibility
of new treatment strategies....................................................................................................... 68

TEST ............................................................................................................................................. 76 

FORUM OF THE CZECH NEUROPSYCHOPHARMACOLOGICAL SOCIETY

Miloslav Kopeček
Will evenamide be the future clozapine in the treatment of resistant schizophrenia?
Positive results of the new glutamate inhibitor
evenamide in study 008A...........................................................................................................77

NEWS

Transcript of Prof. Jan Vevera's speech at the funeral of MUDr. Jan Sikora ............................ 79

Ladislav Csémy a MUDr. Karel Nešpor
Social media and addictive behaviour........................................................................................ 81

CORRESPONDENCE

Radkin Honzák
Spirituality and medicine............................................................................................................. 83

SUBSCRIPTION

OBSAH

EDITORIAL

Miloslav Kopeček ............................................................................................................ 1

OBSAH............................................................................................................................. 3

PŮVODNÍ PRÁCE

Veronika Boleková, Filip Foriš
Typológia ľudí závislých od alkoholu z hľadiska ich kognitívnych výkonov ...................... 5

PŘEHLEDNÉ ČLÁNKY

Jiří Patočka, Zdeňka Navrátilová, Patrik Olekšák
Trehalóza – disacharid s neuroprotektivním účinkem ...................................................... 11

KAZUISTIKY

Miloslav Kopeček, Veronika Andrashko, Jiří Renka
Průlomová a udržovací léčba rezistentní depresivní
poruchy racemickým ketaminem – kazuistická studie ...................................................... 16

VZDĚLÁVÁNÍ

Klára Látalová
Základní farmakologická léčba generalizované úzkostné poruchy ................................... 20

FÓRUM ČESKÉ NEUROPSYCHOFARMAKOLOGICKÉ SPOLEČNOSTI

Martin Hýža, Petr Šilhán, David Škrda, Jan Vober, Jan Uhlíř,
Petr Dostálek, Tomáš Skřont, Samuel Ambroš, Eva Češková
Terapeutické monitorování psychofarmak 3:
využití u jednotlivých lékových skupin............................................................................... 27

ZPRÁVY

Petra Horáková 
67. česko-slovenská psychofarmakologická konference,
10.–14. 1. 2024, Mariánské Lázně.................................................................................... 37

DOPISY, OHLASY, DISKUZE

Miloslav Kopeček
`Pilotní studie škály PHQ-9 u studentů 5. ročníku 3. lékařské fakulty
Univerzity Karlovy v Praze................................................................................................ 39

Karel Nešpor
Účinky tělesné aktivity na psychiku................................................................................... 42

Václav Filip
Psychedelika u deprese a vizionář Ladislav Haškovec.................................................... 43

PŘEDPLATNÉ.............................................................................................................44 

 

CONTENTS

EDITORIAL

Miloslav Kopeček ............................................................................................................ 1

CONTENTS..................................................................................................................... 3

ORIGINAL PAPERS

Veronika Boleková, Filip Foriš
Cognitive performance-based typology of people with alcohol use disorders................... 5

REVIEWS

Jiří Patočka, Zdeňka Navrátilová, Patrik Olekšák
Trehalose – disaccharide with a neuroprotective effect .................................................. 11

CASE REPORTS

Miloslav Kopeček, Veronika Andrashko, Jiří Renka
Breakthrough and maintenance treatment of resistant
depressive disorder by racemic ketamine – a case study................................................ 16

CME

Klára Látalová
Basic pharmacological treatment of generalized anxiety disorder ................................... 20

FORUM OF THE CZECH NEUROPSYCHOPHARMACOLOGICAL SOCIETY

Martin Hýža, Petr Šilhán, David Škrda, Jan Vober, Jan Uhlíř,
Petr Dostálek, Tomáš Skřont, Samuel Ambroš, Eva Češková
Therapeutic monitoring of psychopharmaceuticals 3:
use for individual drug groups........................................................................................... 27

NEWS

Petra Horáková
67. Czech-Slovak Psychopharmacological Conference,
10.–14. 1. 2024, Mariánské Lázně.................................................................................... 37

CORRESPONDENCE

Miloslav Kopeček
Pilot study of the PHQ-9 scale in 5th year students of the 3rd Medical
Faculty of Charles University in Prague........................................................................... 39

Karel Nešpor
Effects of physical activity on the psyche.......................................................................... 42

Václav Filip
Psychedelics in depression and the visionary Ladislav Haškovec................................... 43

SUBSCRIPTION......................................................................................................... 44

psych SUPPL obalka 1 2024 web

Psychiatrie supplementum 1/2024

EDITORIAL .............................................................................................................. 1

OBSAH .................................................................................................................... 2

PROGRAM .............................................................................................................. 4

ODBORNÁ SYMPOZIA ........................................................................................... 9
Psychotická deprese ................................................................................................ 9

Zánět a psychotické poruchy: 2. část ..................................................................... 10
Sympózium Psychofarmakologickej sekcie SPsS SLS .......................................... 11
Současné trendy neurostimulace v klinické praxi ................................................... 12
Farmakoterapie a psychoterapie: spolu, nebo zvlášť? ........................................... 14
Obtížně léčebně ovlivnitelné příznaky schizofrenie ................................................ 14

Hříchy psychofarmakologické léčby ........................................................................ 15
Gama-6 a gama-3-mastné kyseliny – vývojová heterogenita –
odlišný biologický význam ....................................................................................... 15

Farmaka a poruchy příjmu potravy: Aktuální možnosti a problémy ......................... 16
Vojenská psychiatrie: Od válek v Jugoslávii do napadení Ukrajiny ......................... 18
Sympozium Společnosti pro biologickou psychiatrii:
Neuropsychiatrické poruchy a jejich léčba ............................................................... 18

Konspirační teorie v lékařské praxi .......................................................................... 20
Jak se vyhnout pastem psychofarmakoterapie: nebezpečí, limity a možnosti ......... 20

Léčba závislostí ........................................................................................................ 21
Sympozium PS ČLS JEP: Konopné drogy regulovat, či neregulovat? ..................... 22
Závislosti v gerontopsychiatrii ................................................................................... 23
Psychedelika, problémové děti psychofarmakologie IV ............................................ 24

NOVÝ VÝZKUM ........................................................................................................ 26
Pilíře klinické predikce antidepresivního efektu ketaminu ......................................... 26
Úloha přední cingulární kůry v inhibiční kontrole –
studie ACDC TMS u pacientů s obsedantně-kompulzivní poruchou ......................... 26
Fenokonverze metabolizmu olanzapinu kouřením .................................................... 27
Dopad léčby předčasné ejakulace na sexuální život žen .......................................... 27
Psychopatologie a kvalita života u onemocnění schizofrenního spektra:
katamnéza po 5 letech .............................................................................................. 27

VÝVĚSKOVÁ SDĚLENÍ ........................................................................................... 28
Preklinická P1–P11 .................................................................................................. 28

Klinická K1–K12 ....................................................................................................... 33

WORKSHOPY .......................................................................................................... 37
Psychiatrický drift: Slepé uličky v životě psychiatra .................................................. 37
Závislosti v praxi: 4 pilíře účinné farmakoterapie ...................................................... 37
Tajemství nevědomí: Thanatos a psychopatologie ................................................... 37
Různé cesty podání ketaminu v ambulaci i během hospitalizace ............................. 38

REJSTŘÍK ................................................................................................................. 39

POKYNY AUTORŮM ................................................................................................. 40

 

EDITORIAL .................................................................................................................. 1

CONTENTS ................................................................................................................. 2

PROGRAMME ............................................................................................................. 4

SCIENTIFIC SYMPOSIA ............................................................................................. 9
Psychotic depression ................................................................................................... 9

Inflammation and psychotic disorders: part 2 ............................................................. 10
Symposium of the Psychopharmacological section
of the Slovak Psychiatric Society ................................................................................ 11

Current trends of neurostimulation in clinical practice ................................................ 12
Pharmacotherapy and psychotherapy: together or separately? ................................. 14
Schizophrenia symptoms that are difficult to treat ...................................................... 14

Sins of psychopharmacological treatment .................................................................. 15
Gamma-6 and gamma-3-fatty acids – developmental heterogeneity –
different biological significance ................................................................................... 15

Pharmacology and eating disorders: Current options and issues ............................... 16
Military psychiatry: From the wars in Yugoslavia to the invasion of Ukraine ............... 18
Symposium of the Society for Biological Psychiatry (SBP) –
Neuropsychiatric disorders and their treatment ........................................................... 18

Conspiracy theories in medical practice ....................................................................... 20
Avoiding the pitfalls of psychopharmacotherapy:
dangers, limits and possibilities .................................................................................... 20

Treatment of addictions ................................................................................................ 21
Symposium of Czech Psychiatric Association:
To regulate or not to regulate cannabis drugs? ............................................................ 22

Addictions in gerontopsychiatry .................................................................................... 23
Psychedelics, problem children of psychopharmacology IV ......................................... 24

NEW RESEARCH ......................................................................................................... 26
Key clinical predictors of the antidepressant effect of ketamine .................................... 26
The role of the anterior cingulate cortex in inhibitory control –
the ACDC TMS study with patients with obsessive-compulsive disorder ...................... 26
Phenoconversion of olanzapine metabolism by smoking .............................................. 27
Impact of treatment of premature ejaculation on the sexual functions of women .......... 27
Psychopathology and quality of life in schizophrenia spectrum disorders:
five-year follow-up .......................................................................................................... 27

POSTERS ...................................................................................................................... 28
Preclinical P1–P11 ......................................................................................................... 28

Clinical K1–K12 .............................................................................................................. 33

WORKSHOPS ................................................................................................................ 37
Psychiatric drift: Blind alleys in the life of a psychiatrist .................................................. 37
Addictions in practice: 4 pillars of effective pharmacotherapy ........................................ 37
Secrets of the unconscious: Thanatos and psychopathology ......................................... 37
Different routes of ketamine administration in ambulatory
care and during hospitalization ....................................................................................... 38

INDEX ............................................................................................................................. 39

INSTRUCTION FOR AUTHORS .................................................................................... 40

Strana 1 z 13